Genmab Lands Potential $1.1B J&J Cancer Drug Deal
Danish drugmaker Genmab A/S has licensed a multiple myeloma treatment to Johnson & Johnson subsidiary Janssen Biotech Inc. in a potential $1.1 billion development and commericalization deal, the companies announced Thursday....To view the full article, register now.
Already a subscriber? Click here to view full article